.jpeg)
2026-08-28 06:51:52
In August 2026, the U.S. FDA granted accelerated approval to daraxonrasib (Rasonque), an oral RAS(ON) inhibitor developed by Revolution Medicines. The drug significantly improves survival in metastatic pancreatic cancer, reshaping the treatment landscape.
2026-08-27 05:38:45
In August 2026, the FDA approved zanidatamab (Ziihera) in combination with tislelizumab and chemotherapy for HER2-positive advanced gastroesophageal adenocarcinoma, achieving a median OS of 26.4 months. This article details the clinical data, indications, safety warnings, and dosing guidelines.
2026-08-24 07:36:03
Two neurokinin receptor antagonists—fezolinetant and elinzanetant—have been approved as non-hormonal therapies for menopausal vasomotor symptoms. Data from the 2026 NIRVANA trial further confirm elinzanetant's efficacy in improving menopause-related sleep disturbances.
2026-08-18 03:25:17
In August 2026, the FDA approved Tauklarify (florquinitau F-18 injection, MK-6240), a radioactive diagnostic agent for PET imaging of tau neurofibrillary tangles in adult patients with cognitive impairment being evaluated for Alzheimer's disease.
2026-08-17 07:50:41
Bristol Myers Squibb announced FDA approval of Zenbexus (iberdomide) in combination with the ZDd regimen for adults with multiple myeloma who have received at least one prior line of therapy — the first approved CELMoD therapy.
2026-08-10 06:59:18
On August 6, 2026, Moderna’s mRNA seasonal influenza vaccine mFLUSIVA became the first mRNA flu vaccine approved by the U.S. FDA for adults aged 50 and older, ushering in a new era of mRNA-based influenza prevention.
2026-08-07 06:44:53
On August 5, 2026, the U.S. FDA approved Takeda's oral tablet Orzeyful (oveporexton) for adults with Narcolepsy Type 1 (NT1). As the first-in-class selective OX2 receptor agonist targeting the orexin pathway, Orzeyful moves beyond symptomatic relief to address the underlying orexin deficiency, simultaneously improving excessive daytime sleepiness, cataplexy, and disrupted nighttime sleep.
2026-07-28 05:34:00
On July 24, 2026, Outlook Therapeutics announced FDA approval of Lytenava (bevacizumab-vikg) for neovascular age-related macular degeneration (wet AMD) — the first bevacizumab formulation purpose-built for intravitreal injection.
2026-07-14 05:19:34
On July 6, 2026, AbbVie announced that the European Commission has granted marketing authorization for TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab (R² regimen) for adult patients with relapsed or refractory follicular lymphoma (R/R FL). The approval is based on the pivotal Phase III EPCORE FL-1 trial, which demonstrated a significant reduction in the risk of disease progression or death compared to R² alone, offering a chemotherapy-free, fixed-duration option for patients in Europe.
2026-06-30 03:12:23
A roundup of recent cancer case studies and pharmaceutical innovations, highlighting long-term survivors of advanced malignancies and the debut of China's first global-first bispecific ADC drug.
2026-06-12 02:58:34
This article provides a detailed overview of the results from a multicenter phase 1 clinical trial of Ceralasertib, an ATR kinase inhibitor, in combination with Durvalumab (brand name Imfinzi), a PD-L1 inhibitor, for the treatment of recurrent or metastatic non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). It covers study design, mechanism of action, efficacy data, safety assessment, and the recommended phase 2 dosing regimen, serving as a reference for patients and healthcare professionals on cutting-edge cancer treatments.
2026-06-04 02:35:34
Discover the latest advancements in cancer drug development, innovative targeted therapies, and cutting-edge technologies like proton therapy, bringing new hope to patients with pancreatic, bile duct, and head and neck cancers.
